BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kornberg A, Küpper B, Thrum K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc. 2009;41:2561-2563. [PMID: 19715974 DOI: 10.1016/j.transproceed.2009.06.115] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Ho CL, Chen S, Cheung SK, Leung TWT. Significant Value of 11C-Acetate and 18F-Fluorodeoxyglucose PET/Computed Tomography on 90Y Microsphere Radioembolization for Hepatocellular Carcinoma. PET Clinics 2019;14:459-67. [DOI: 10.1016/j.cpet.2019.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015; 7(4): 649-661 [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
3 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092-1097. [PMID: 22064078 DOI: 10.1097/rlu.0b013e3182335df4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
5 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
6 Berk LB. Hepatocellular carcinoma: fighting the rising tide. Cancer Control 2010;17:68-9. [PMID: 20404789 DOI: 10.1177/107327481001700201] [Reference Citation Analysis]
7 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
8 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 90] [Article Influence: 10.9] [Reference Citation Analysis]
9 Kornberg A, Witt U, Matevossian E, Küpper B, Assfalg V, Drzezga A, Hüser N, Wildgruber M, Friess H. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One. 2013;8:e53960. [PMID: 23349774 DOI: 10.1371/journal.pone.0053960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
10 Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, Hsu CN, Lin CL, Kao CH. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation. Clin Nucl Med. 2017;42:e183-e187. [PMID: 28114226 DOI: 10.1097/rlu.0000000000001545] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
11 Wu YC, Hsieh TC, Sun SS, Yen KY, Kao CH. Bilateral breast uptake demonstrated on FDG PET/CT scans in 3 male patients with hepatocellular carcinomas. Clin Nucl Med 2012;37:520-1. [PMID: 22475911 DOI: 10.1097/RLU.0b013e31823ea993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
12 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu S, Chan KW, Tong J, Wang Y, Wang B, Qiao L. PET-CT scan is a valuable modality in the diagnosis of fibrolamellar hepatocellular carcinoma: a case report and a summary of recent literature. QJM 2011;104:477-83. [DOI: 10.1093/qjmed/hcr040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
15 Wu X, Li J, Wang C, Zhang G, Zheng N, Wang X. Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma. Gastroenterol Res Pract 2016;2016:8763205. [PMID: 26819614 DOI: 10.1155/2016/8763205] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016; 22(12): 3325-3334 [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
17 Gauthé M, Richard-Molard M, Cacheux W, Michel P, Jouve JL, Mitry E, Alberini JL, Lièvre A; Fédération Francophone de Cancérologie Digestive (FFCD). Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Dig Liver Dis 2015;47:443-54. [PMID: 25766918 DOI: 10.1016/j.dld.2015.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
18 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015; 21(42): 12071-12082 [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
19 Ling LL, Hsu C, Yong C, Elsarawy AM, Chan Y, Wang C, Li W, Lin T, Kuo F, Cheng Y, Lin L, Chen C, Lin C. FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study. International Journal of Surgery 2019;69:124-31. [DOI: 10.1016/j.ijsu.2019.07.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
20 Sung PS, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. Eur J Nucl Med Mol Imaging. 2018;45:384-391. [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
21 Chisthi MM. Commentary on "FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study". Int J Surg 2019;70:31-2. [PMID: 31421217 DOI: 10.1016/j.ijsu.2019.08.014] [Reference Citation Analysis]
22 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343 [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
23 Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, Malafa MP. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Clin Nucl Med 2016;41:177-81. [PMID: 26673243 DOI: 10.1097/RLU.0000000000001098] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
24 Kornberg A, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. Sci Rep. 2017;7:14176. [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
25 Sürücü E, Polack BD, Demir Y, Durmuşoğlu M, Ekmekçi S, Sarıoğlu S, Çelik AO, Ada E, İkiz AÖ. Dual-phase F-18 FDG PET–CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers. Clinical Imaging 2015;39:781-6. [DOI: 10.1016/j.clinimag.2015.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
27 Asman Y, Evenson AR, Even-Sapir E, Shibolet O. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma. Liver Transpl. 2015;21:572-580. [PMID: 25644857 DOI: 10.1002/lt.24083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
28 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
29 Bailly M, Venel Y, Orain I, Salamé E, Ribeiro MJ. 18F-FDG PET in Liver Transplantation Setting of Hepatocellular Carcinoma: Predicting Histology? Clin Nucl Med 2016;41:e126-9. [PMID: 26545024 DOI: 10.1097/RLU.0000000000001040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
30 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Hyun SH, Eo JS, Song BI, Lee JW, Na SJ, Hong IK, Oh JK, Chung YA, Kim TS, Yun M. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. 2018;45:720-726. [PMID: 29167923 DOI: 10.1007/s00259-017-3880-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
32 Carr BI, Guerra V, Donghia R, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. Int J Biol Markers 2021;36:54-61. [PMID: 33641486 DOI: 10.1177/1724600821996372] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
34 Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med. 2013;54:1710-1716. [PMID: 23970365 DOI: 10.2967/jnumed.112.119370] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
35 Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. J Nucl Med. 2016;57:1045-1051. [PMID: 26985057 DOI: 10.2967/jnumed.115.170076] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
36 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
37 Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787. [PMID: 21469082 DOI: 10.1002/cncr.26099] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]